Optimal Medical Therapy for Chronic Coronary Disease in 2024 : Focus on Antithrombotic Therapy
Copyright © 2023 Elsevier Inc. All rights reserved..
Antiplatelet therapy is the cornerstone of the secondary prevention of cardiovascular disease. Aspirin is indicated for all patients with chronic coronary disease to prevent recurrent ischemic events. A more potent antithrombotic therapy-including P2Y12 inhibitor monotherapy, dual antiplatelet therapy, or vascular dose anticoagulation-reduces the risk of ischemic events but also increases bleeding risk. Clinicians must weigh both ischemic risks and bleeding risks when determining an optimal antithrombotic therapy for patients with chronic coronary disease, and soliciting patient involvement in shared decision-making is critical.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:108 |
|---|---|
| Enthalten in: |
The Medical clinics of North America - 108(2024), 3 vom: 20. Apr., Seite 489-507 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Patel, Parth P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antithrombotic therapy |
|---|
| Anmerkungen: |
Date Completed 01.04.2024 Date Revised 01.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.mcna.2023.11.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM37037987X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM37037987X | ||
| 003 | DE-627 | ||
| 005 | 20240401232942.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240330s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.mcna.2023.11.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1359.xml |
| 035 | |a (DE-627)NLM37037987X | ||
| 035 | |a (NLM)38548459 | ||
| 035 | |a (PII)S0025-7125(23)00174-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Patel, Parth P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Optimal Medical Therapy for Chronic Coronary Disease in 2024 |b Focus on Antithrombotic Therapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.04.2024 | ||
| 500 | |a Date Revised 01.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a Antiplatelet therapy is the cornerstone of the secondary prevention of cardiovascular disease. Aspirin is indicated for all patients with chronic coronary disease to prevent recurrent ischemic events. A more potent antithrombotic therapy-including P2Y12 inhibitor monotherapy, dual antiplatelet therapy, or vascular dose anticoagulation-reduces the risk of ischemic events but also increases bleeding risk. Clinicians must weigh both ischemic risks and bleeding risks when determining an optimal antithrombotic therapy for patients with chronic coronary disease, and soliciting patient involvement in shared decision-making is critical | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Antithrombotic therapy | |
| 650 | 4 | |a Chronic coronary disease | |
| 650 | 4 | |a Coronary artery disease | |
| 650 | 7 | |a Platelet Aggregation Inhibitors |2 NLM | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 650 | 7 | |a Aspirin |2 NLM | |
| 650 | 7 | |a R16CO5Y76E |2 NLM | |
| 700 | 1 | |a Fanaroff, Alexander C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Medical clinics of North America |d 1945 |g 108(2024), 3 vom: 20. Apr., Seite 489-507 |w (DE-627)NLM000062588 |x 1557-9859 |7 nnns |
| 773 | 1 | 8 | |g volume:108 |g year:2024 |g number:3 |g day:20 |g month:04 |g pages:489-507 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.mcna.2023.11.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 108 |j 2024 |e 3 |b 20 |c 04 |h 489-507 | ||